Table 3. Vaccine Completion in 1 and 2 Months by Messaging Content.
| Messaging content | No. | Dose 1 completion at 1 mo | Dose 1 completion at 2 mo | Series completion at 2 moa | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Completion, No. (%) [95% CI] | Difference, % (95% CI) | P valueb | Completion, No. (%) [95% CI] | Difference, % (95% CI) | P valueb | Completion, No. (%) [95% CI] | Difference, % (95% CI) | P valueb | ||
| Standard messaging | 3889 | 118 (3.0) [2.5 to 3.6] | NA | NA | 158 (4.1) [3.4 to 4.7] | NA | NA | 104 (2.7) [2.2 to 3.2] | NA | NA |
| Clinician endorsement | 3920 | 135 (3.4) [2.9 to 4.0] | 0.4 (−0.4 to 1.2) | .31 | 177 (4.5) [3.9 to 5.2] | 0.5 (−0.4 to 1.4) | .32 | 127 (3.2) [2.7 to 3.8] | 0.6 (−0.2 to 1.3) | .14 |
| Scarcity | 3911 | 100 (2.6) [2.1 to 3.1] | −0.5 (−1.2 to 0.3) | .20 | 141 (3.6) [3.0 to 4.2] | −0.5 (−1.3 to 0.4) | .29 | 95 (2.4) [1.9 to 2.9] | −0.2 (−0.9 to 0.5) | .49 |
| Endowment | 3935 | 143 (3.6) [3.0 to 4.2] | 0.6 (−0.2 to 1.4) | .14 | 181 (4.6) [3.9 to 5.3] | 0.5 (−0.4 to 1.4) | .24 | 127 (3.2) [2.7 to 3.8] | 0.6 (−0.2 to 1.3) | .15 |
Abbreviation: NA, not applicable.
a
Completed 2 doses of the mRNA-1273 [Moderna] or BNT162b2 [BioNTech-Pfizer] vaccine or 1 dose of the Ad.26.COV2.S [Janssen] vaccine.
b
P < .025 was the threshold for statistical significance using the Bonferroni correction for multiple comparisons and an overall type I error rate of .05 (.05/3).